Focusing on our 22 breast cancer samples, 13 patients had received Anti-HER2 ERBB2 (Human Epidermal Growth Factor Receptor 2) gene therapy, despite only 11 showing HER2 ERBB2 positivity in their primary tumor samples, and ten of these showing the same positivity in their metastatic tumors. This evidence concerns the gene ERBB2 and breast carcinoma.